S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:KMDA

Kamada - KMDA Stock Forecast, Price & News

$4.57
-0.01 (-0.22%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.49
$4.58
50-Day Range
$4.13
$4.84
52-Week Range
$4.11
$6.96
Volume
45,741 shs
Average Volume
48,537 shs
Market Capitalization
$204.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KMDA stock logo

About Kamada (NASDAQ:KMDA) Stock

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Stock News Headlines

Kamada (NASDAQ:KMDA) Now Covered by Analysts at StockNews.com
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update
Kamada (KMDA) Q3 Earnings and Revenues Top Estimates
Kamada Ltd. (KMDA.TA)
See More Headlines
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Company Calendar

Last Earnings
11/21/2021
Today
12/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMDA
Employees
355
Year Founded
N/A

Profitability

Net Income
$-2,230,000.00
Pretax Margin
-8.55%

Debt

Sales & Book Value

Annual Sales
$103.64 million
Cash Flow
$0.11 per share
Book Value
$3.95 per share

Miscellaneous

Free Float
N/A
Market Cap
$204.74 million
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Mr. Amir London (Age 53)
    Chief Exec. Officer
    Comp: $522k
  • Mr. Chaime Orlev (Age 52)
    Chief Financial Officer
    Comp: $331k
  • Mr. Eran Nir (Age 49)
    Chief Operating Officer
    Comp: $322k
  • Ms. Yifat Philip Esq. (Age 45)
    VP of Legal, Gen. Counsel & Corp. Sec.
    Comp: $247k
  • Mr. David Tsur (Age 72)
    Co-Founder & Deputy Chairman
  • Ms. Hanni Neheman (Age 52)
    VP of Marketing & Sales
  • Ms. Ariella Raban (Age 46)
    VP of HR
  • Mr. Jon R. Knight
    VP of US Commercial Operations













KMDA Stock - Frequently Asked Questions

How have KMDA shares performed in 2022?

Kamada's stock was trading at $6.58 at the beginning of 2022. Since then, KMDA shares have decreased by 30.5% and is now trading at $4.57.
View the best growth stocks for 2022 here
.

Are investors shorting Kamada?

Kamada saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 500,700 shares, an increase of 5.1% from the October 31st total of 476,500 shares. Based on an average daily volume of 33,200 shares, the short-interest ratio is currently 15.1 days. Currently, 1.3% of the company's shares are short sold.
View Kamada's Short Interest
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Sunday, November, 21st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.05. The biotechnology company earned $23.03 million during the quarter, compared to analyst estimates of $25.20 million. Kamada had a positive trailing twelve-month return on equity of 0.91% and a negative net margin of 8.91%. During the same period in the prior year, the business posted $0.15 EPS.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2022 earnings guidance on Tuesday, November, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $125.00 million-$135.00 million, compared to the consensus revenue estimate of $127.83 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by many different institutional and retail investors. Top institutional shareholders include Phoenix Holdings Ltd. (4.60%), Altshuler Shaham Ltd (2.05%), Renaissance Technologies LLC (1.97%), Vanguard Group Inc. (1.93%), Migdal Insurance & Financial Holdings Ltd. (0.76%) and BlackRock Inc. (0.42%).

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $4.57.

How much money does Kamada make?

Kamada (NASDAQ:KMDA) has a market capitalization of $204.74 million and generates $103.64 million in revenue each year. The biotechnology company earns $-2,230,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Kamada have?

The company employs 355 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.

This page (NASDAQ:KMDA) was last updated on 12/8/2022 by MarketBeat.com Staff